The Cambridge, US-based startup Suono Bio is developing a breakthrough technology that enable rapid delivery of therapeutics to the gastrointestinal tract. The innovative device enable delivery of a broad class of therapeutics to be achieved in only one minute, and it has been demonstrated to be both safe and effective in preclinical studies. While the treatment is still administered through an enema, Suono Bio’s device use ultrasound waves to push the therapeutics into the tissue of the gastrointestinal tract, allowing the body to absorb the medicine faster.
While current treatment options are administered through enemas, they must remain in the colon for hours while the drug is absorbed, which can be difficult for patients suffering from diarrhea. The new technology could help millions of people who suffer from gastrointestinal disorders worldwide, absorbing the drugs in minutes instead of hours. And although patients with gastrointestinal disorders would be the most obvious to benefit, the method could also help deliver drugs to patients with colon cancer or gastrointestinal infections, highlighting the huge potential of the technology. It could increase the efficacy of current treatment options, improving quality of life, save lives, and give new hope to patients who have run out of alternatives.
Suono Bio was founded by Carl Shoellhammer, who has also invested the mPill, a small plastic device covered with tiny needles and a protective coating that dissolves, and was named a Forbes 30 under 30 in healthcare. Suono bio reached the finals of MIT’s prestigious $100K pitch competition, and is also one of the finalists at OneStart, the world’s largest life sciences and healthcare startup accelerator program.